SG11201401817TA - 7-{(3s,4s)-3-[(cyclopropylamino)methyl]-4-fluoropyrrolidine-1-yl}-6-fluoro-1-(2-fluoroethyl)-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid crystal - Google Patents

7-{(3s,4s)-3-[(cyclopropylamino)methyl]-4-fluoropyrrolidine-1-yl}-6-fluoro-1-(2-fluoroethyl)-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid crystal

Info

Publication number
SG11201401817TA
SG11201401817TA SG11201401817TA SG11201401817TA SG11201401817TA SG 11201401817T A SG11201401817T A SG 11201401817TA SG 11201401817T A SG11201401817T A SG 11201401817TA SG 11201401817T A SG11201401817T A SG 11201401817TA SG 11201401817T A SG11201401817T A SG 11201401817TA
Authority
SG
Singapore
Prior art keywords
fluoropyrrolidine
cyclopropylamino
dihydroquinoline
fluoroethyl
oxo
Prior art date
Application number
SG11201401817TA
Other languages
English (en)
Inventor
Ichiro Araya
Akinori Goto
Wataru Minagawa
Keiko Funada
Muneki Nagao
Original Assignee
Kyorin Seiyaku Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48289529&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201401817T(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kyorin Seiyaku Kk filed Critical Kyorin Seiyaku Kk
Publication of SG11201401817TA publication Critical patent/SG11201401817TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
SG11201401817TA 2011-11-10 2012-11-09 7-{(3s,4s)-3-[(cyclopropylamino)methyl]-4-fluoropyrrolidine-1-yl}-6-fluoro-1-(2-fluoroethyl)-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid crystal SG11201401817TA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2011246209 2011-11-10
JP2012071739 2012-03-27
PCT/JP2012/007195 WO2013069297A1 (ja) 2011-11-10 2012-11-09 ７－｛（３s、４s）－３－［（シクロプロピルアミノ)メチル］－４－フルオロピロリジン－1－イル｝－６－フルオロ－１－（２－フルオロエチル）－８－メトキシ－４－オキソ－１、４－ジヒドロキノリン－３－カルボン酸の結晶

Publications (1)

Publication Number Publication Date
SG11201401817TA true SG11201401817TA (en) 2014-08-28

Family

ID=48289529

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201608167UA SG10201608167UA (en) 2011-11-10 2012-11-09 7-{(3s,4s)-3-[(cyclopropylamino)methyl]-4-fluoropyrrolidine-1-yl}-6-fluoro-1-(2-fluoroethyl)-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid crystal
SG11201401817TA SG11201401817TA (en) 2011-11-10 2012-11-09 7-{(3s,4s)-3-[(cyclopropylamino)methyl]-4-fluoropyrrolidine-1-yl}-6-fluoro-1-(2-fluoroethyl)-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid crystal

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201608167UA SG10201608167UA (en) 2011-11-10 2012-11-09 7-{(3s,4s)-3-[(cyclopropylamino)methyl]-4-fluoropyrrolidine-1-yl}-6-fluoro-1-(2-fluoroethyl)-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid crystal

Country Status (17)

Country Link
US (3) US9090587B2 (enExample)
EP (2) EP3112359B1 (enExample)
JP (4) JP5871948B2 (enExample)
KR (2) KR102162208B1 (enExample)
CN (2) CN103930414B (enExample)
AU (1) AU2016273899B2 (enExample)
BR (1) BR112014010765B1 (enExample)
CA (1) CA2855022C (enExample)
ES (2) ES2621664T3 (enExample)
IN (1) IN2014DN03277A (enExample)
MX (1) MX375073B (enExample)
NZ (1) NZ623808A (enExample)
RU (2) RU2017109814A (enExample)
SA (1) SA112330992B1 (enExample)
SG (2) SG10201608167UA (enExample)
TW (1) TWI547492B (enExample)
WO (1) WO2013069297A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SA112330992B1 (ar) * 2011-11-10 2015-09-13 كيورين فارماسوتيكال كو.، ليمتد صورة متبلرة من 7-{(s4، s3)-3-[(سيكلو بروبيل أمينو) ميثيل]-4-فلورو بيروليدين-1-يل}-6-فلورو-1-(2-فلورو إيثيل)- 8-ميثوكسي-4-أوكسو-1، 4-داي هيدرو كينولين-3- حمض كربوكسيلي
WO2014174848A1 (ja) * 2013-04-25 2014-10-30 杏林製薬株式会社 錠剤
ES2768651T3 (es) 2013-04-25 2020-06-23 Kyorin Seiyaku Kk Composición farmacéutica sólida
EP2990039A4 (en) * 2013-04-25 2017-02-22 Kyorin Pharmaceutical Co., Ltd. Solid pharmaceutical composition
GB201402071D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
CA2965473A1 (en) * 2014-10-23 2016-04-28 Kyorin-Pharmaceutical Co., Ltd. Solid pharmaceutical composition
JP6832706B2 (ja) * 2014-10-23 2021-02-24 杏林製薬株式会社 固形医薬組成物
CN113975277B (zh) * 2015-03-13 2024-10-18 杏林制药株式会社 呼吸器官感染治疗剂
WO2016195021A1 (ja) 2015-06-02 2016-12-08 杏林製薬株式会社 水性液剤
WO2016195020A1 (ja) * 2015-06-02 2016-12-08 杏林製薬株式会社 水性液剤
CA2987879A1 (en) 2015-06-02 2016-12-08 Kyorin Pharmaceutical Co., Ltd. Aqueous drug
WO2018230686A1 (ja) 2017-06-16 2018-12-20 杏林製薬株式会社 誤嚥性肺炎、肺化膿症又は肺膿瘍の治療剤
JP6618660B2 (ja) 2017-06-16 2019-12-11 杏林製薬株式会社 誤嚥性肺炎、肺化膿症又は肺膿瘍の治療剤
GB201808575D0 (en) 2018-05-24 2018-07-11 Galapagos Nv Methods for the treatment of psoriatic arthrits

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA944369B (en) * 1993-08-27 1995-02-13 Hokuriku Seuyaku Co Ltd 5-amino-8-methyl-7-pyrrolidinylquinoline-3-carboxylic acid derivative
CN1158846A (zh) * 1995-05-09 1997-09-10 昆山市康壮达兽药厂 盐酸氟哌酸的合成工艺
US20030118078A1 (en) * 2001-08-10 2003-06-26 Carlson Eric D. Apparatuses and methods for creating and testing pre-formulations and systems for same
WO2003076428A1 (en) * 2002-03-08 2003-09-18 Daiichi Pharmaceutical Co., Ltd. Quinolonecarboxylic acid derivative
WO2005026147A1 (ja) 2003-09-10 2005-03-24 Kyorin Pharmaceutical Co., Ltd. ７−（４−置換−３−シクロプロピルアミノメチル−１−ピロリジニル）キノロンカルボン酸誘導体
CN101003540A (zh) * 2006-01-18 2007-07-25 广州白云山制药股份有限公司广州白云山制药总厂 一种抗感染化合物和用途
SA112330992B1 (ar) * 2011-11-10 2015-09-13 كيورين فارماسوتيكال كو.، ليمتد صورة متبلرة من 7-{(s4، s3)-3-[(سيكلو بروبيل أمينو) ميثيل]-4-فلورو بيروليدين-1-يل}-6-فلورو-1-(2-فلورو إيثيل)- 8-ميثوكسي-4-أوكسو-1، 4-داي هيدرو كينولين-3- حمض كربوكسيلي

Also Published As

Publication number Publication date
BR112014010765A2 (pt) 2017-06-13
NZ623808A (en) 2015-07-31
AU2012337206A1 (en) 2014-05-22
US9328089B2 (en) 2016-05-03
CN104945375A (zh) 2015-09-30
EP3112359B1 (en) 2019-08-21
CN103930414A (zh) 2014-07-16
KR20140098074A (ko) 2014-08-07
MX375073B (es) 2025-03-06
JP2017160243A (ja) 2017-09-14
EP2778159B1 (en) 2017-03-01
US20140288310A1 (en) 2014-09-25
AU2016273899B2 (en) 2017-07-27
US9090587B2 (en) 2015-07-28
EP3112359A1 (en) 2017-01-04
EP2778159A1 (en) 2014-09-17
EP2778159A4 (en) 2015-06-03
CA2855022C (en) 2019-05-07
RU2615509C2 (ru) 2017-04-05
JP2018158949A (ja) 2018-10-11
JP5871948B2 (ja) 2016-03-01
IN2014DN03277A (enExample) 2015-05-22
SG10201608167UA (en) 2016-11-29
RU2014123567A (ru) 2015-12-20
WO2013069297A1 (ja) 2013-05-16
TW201332991A (zh) 2013-08-16
BR112014010765B1 (pt) 2020-07-14
AU2016273899A1 (en) 2017-01-12
ES2621664T3 (es) 2017-07-04
JP2016027045A (ja) 2016-02-18
JP6818719B2 (ja) 2021-01-20
AU2012337206A8 (en) 2016-09-22
CN103930414B (zh) 2016-01-20
CN104945375B (zh) 2017-07-04
TWI547492B (zh) 2016-09-01
SA112330992B1 (ar) 2015-09-13
JPWO2013069297A1 (ja) 2015-04-02
CA2855022A1 (en) 2013-05-16
ES2747303T3 (es) 2020-03-10
AU2012337206B2 (en) 2016-09-15
JP6349435B2 (ja) 2018-06-27
US20150284361A1 (en) 2015-10-08
KR102162208B1 (ko) 2020-10-06
RU2017109814A (ru) 2019-01-23
RU2017109814A3 (enExample) 2020-04-08
KR20190065456A (ko) 2019-06-11
JP6514069B2 (ja) 2019-05-15
USRE47785E1 (en) 2019-12-31

Similar Documents

Publication Publication Date Title
SG10201608167UA (en) 7-{(3s,4s)-3-[(cyclopropylamino)methyl]-4-fluoropyrrolidine-1-yl}-6-fluoro-1-(2-fluoroethyl)-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid crystal
GB2509841B (en) Universal Arm System
ZA201406639B (en) Stabilized hypohalous acid solutions
BR112014029261A2 (pt) compostos de ácido carboxílico
AP4063A (en) Dimethyl-benzoic acid compounds
EP2660214A4 (en) Crystallized glass
EP2750908B8 (en) Cooling system
SG11201403205SA (en) Process for making levulinic acid
EP2897909A4 (en) ELIMINATION OF CYANURIC ACID
SI2757103T1 (sl) Derivati pirolidin-3-ilocetne kisline
SG11201403142PA (en) Novel acetic acid ester compound or salt thereof
AU2010905634A0 (en) Processes for preparing 8-hydroxy quinoline derivatives
AU2011900159A0 (en) Process for capturing acid gases
AU2011905028A0 (en) E-trakka equine stride length system
AU2012900017A0 (en) Processes for preparing 8-hydroxy quinoline derivatives
IL215542A0 (en) Aerial identification system
AU2011900024A0 (en) Livestock handling system
AU2011901504A0 (en) Display System
ZA201306884B (en) Stabilized hypohalous acid solutions
AU2011904058A0 (en) Positioning system
AU2011900833A0 (en) Improved Optical Aisle System
AU2012902253A0 (en) Improved Electronic Display System
AU2012903692A0 (en) Vegetation support system
AU2011902245A0 (en) Optical system
AU2011902249A0 (en) Optical system